A Guide to Cancer Stem Cell Markers

Cancer Stem Cells (CSCs) are a rare subset of tumor cells (typically ~1–3%) that drive tumor initiation, growth, metastasis, and relapse. Because of their critical role, identifying biomarkers that characterize CSCs is vital for diagnosis, prognosis, and therapy. Selectively targeting CSCs (e.g., with antibodies) is a promising strategy to improve cancer treatment outcomes.

Major Cancer Stem Cell Markers

Here are some of the most prominent CSC markers, categorized by type, and their biological relevance.

Surface (Cell-Surface) Markers

Surface markers are commonly used to isolate CSC populations because they can be detected and sorted without disrupting the cell. Key examples include CD44, a hyaluronic-acid receptor linked to adhesion and metastasis; CD133 (Prominin-1), widely used to define tumor-initiating cells across multiple cancer types; EpCAM, an epithelial adhesion molecule enriched in many solid tumors; and CD24, which complements CD44 to distinguish stem-like subpopulations in breast and other cancers.

Intracellular / Enzymatic Markers

Intracellular markers often reflect metabolic activity, differentiation state, or transcriptional control within CSCs. ALDH1A1, a member of the aldehyde dehydrogenase family, is one of the most established functional CSC markers due to its high enzymatic activity in stem-like cells. Transcription factors such as SOX2, OCT4, and NANOG denote self-renewal programs, while signaling-associated proteins like β-catenin mark activation of pathways (e.g., Wnt) known to maintain stemness.

TABLE 1. Key Cancer Stem Cell Markers: Types, Cancer Associations, and Functional Notes

Clinical & Prognostic Significance of CSC Markers

Cancer stem cell (CSC)–associated markers play a major role in shaping how tumors behave, recur, and respond to therapy. Their expression patterns provide powerful insight into disease aggressiveness, treatment resistance, and long-term patient outcomes.

Below are clear, cancer-specific examples illustrating how CSC markers function as clinically relevant prognostic indicators.

Cholangiocarcinoma (CCA)

In CCA, elevated levels of CD44—including specific splice variants—CD133, and EpCAM show strong association with tumor recurrence. When these CSC markers are assessed together with classical serum markers such as CA19-9, predictive accuracy for relapse improves significantly.

Ovarian Cancer

ALDH1A1 functions as an independent prognostic indicator in ovarian tumors. High ALDH1A1 expression correlates with shorter overall survival (OS) and reduced progression-free survival (PFS), marking a clinically meaningful CSC-linked phenotype.

Breast Cancer

Breast tumors enriched for CD44⁺/CD24⁻ or ALDH-high populations display more aggressive clinical trajectories. These CSC-associated signatures align with increased metastatic potential, reduced responsiveness to chemotherapy, and shorter disease-free intervals.

Colorectal Cancer (CRC)

CRC demonstrates strong prognostic ties to LGR5, EpCAM, and CD133/PROM1. High expression of these markers—especially in the invasive tumor front—correlates with elevated recurrence risk and enhanced metastatic behavior following surgical resection.

How to Select Your CSC Targets in 3 Steps

The Human Protein Atlas (HPA) gives you a clean, evidence-based path for choosing and validating cancer stem cell (CSC) targets. By pulling data from both the Cancer Atlas and the Cell Line Atlas, you can confirm clinical relevance and select appropriate experimental models with confidence.

STEP 1: Establish Clinical Relevance (Cancer Atlas)
Begin by checking whether your candidate CSC marker shows prognostic value in patient cohorts. For example, the Cancer Atlas provides Kaplan–Meier survival curves that reveal how high SOX2 expression correlates with poor survival in lung cancer. This step anchors your target in real clinical outcomes.

STEP 2: Select an Appropriate Model System (Cell Line Atlas)
Once clinical relevance is clear, the Cell Line Atlas helps you identify which cancer cell lines express your target at meaningful levels. If SOX2 is your marker, you might find that lines such as A549 exhibit high RNA expression, making them suitable and biologically consistent models for in vitro experiments.

STEP 3: Select Validated Antibodies for Your Target (atlasantibodies.com)
With your marker identified and an appropriate model system chosen, the final step is selecting high-quality antibodies for your experiments. At atlasantibodies.com, you can search for your CSC marker and choose from a range of polyclonal and monoclonal antibodies, depending on your experimental needs. Each product includes detailed validation data for key applications—such as IHC, WB, ICC/IF and ChIP, so you can match the right marker to your workflow with confidence. This ensures that every experiment you run remains aligned with rigorously validated, consistent tools.

The Atlas Antibodies Advantage

• Rooted in the Human Protein Atlas: Our products are developed and qualified using the vast, open-access data from the HPA project.
• Application-Specific Enhanced Validation: We provide industry-leading transparency. You can see how our antibodies perform in IHC, WB, and ICC-IF across all major human tissues and cancer types.
• Evidenced by Science: With over 15,000 product citations, our antibodies are trusted by researchers worldwide to deliver specific and reproducible results.

Conclusion

Cancer stem cell markers are a powerful tool in cancer biology as they help us isolate, understand, and, most importantly, target the cells that fuel tumor growth and relapse. However, due to heterogeneity and plasticity, we need multi-marker strategies and rigorous functional validation. The future of CSC research lies in integrating molecular profiling, antibody-based targeting, and precision oncology to more effectively eliminate these dangerous “roots” of cancer.

Download the complete CSC Marker Guide 

• CSC markers for solid tumors (Lung, Breast, Liver, etc)
• CSC markers for hematological tumors (AML, CML)
• Full extracellular (CD) and intracellular marker lists
• Key reference and IHC validation data

DOWNLOAD NOW